UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
ADNOC Gas Targets Up to $4B Profit in 2026 
US Judge Dismisses Gautam Adani Criminal Charges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Airbus Joins Air India A320 Altitude Drop Probe 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in the second round of U.S. government-led Medicare drug price negotiations, a federal health agency confirmed Friday.
The negotiations, originally established under the Inflation Reduction Act of 2022, will now proceed under President Donald Trump’s administration, which has pledged greater transparency following industry pushback on Biden-era policies.
The Centers for Medicare & Medicaid Services (CMS) stated that the discussions would involve significant engagement with drugmakers and the public. CMS will submit an initial pricing proposal for each drug by June 1, with companies given 30 days to accept or counteroffer. If no agreement is reached, additional meetings will be scheduled through November 1.
Among the 15 drugs selected for Medicare price talks for 2027 are Novo Nordisk’s widely used diabetes drug Ozempic and weight-loss treatment Wegovy. The list also includes Pfizer’s (NYSE:PFE) cancer drugs Ibrance and Xtandi, Teva’s Austedo for Huntington’s disease, and AbbVie’s (NYSE:ABBV) Linzess for bowel syndrome.
The pharmaceutical industry has criticized the government’s pricing efforts, arguing that they could impact innovation and investment in drug development. However, CMS maintains that negotiations will ensure fair pricing for Medicare beneficiaries while fostering transparency in the process.
With healthcare costs remaining a major issue, the outcome of these negotiations could reshape pricing strategies for blockbuster drugs. Investors, patients, and industry stakeholders will closely monitor the developments as the talks progress through 2024 and beyond.
